Search results

1. Sanofi’s Sarclisa gets one up on Darzalex

   … 84% with Darzalex + VRd vs 68% with VRd Late-breaker at ASH 2023 Note: all involved CD38 antibodies being …

   
    

   Madeleine Armstrong
    
   - 12/09/2023 - 22:21

2. Crispr abandons first-generation Car-T projects

   … BCMA NCT04960579 in 2L MM; initial data at ASH 2023 Poseida claims several design features that it …

   
    

   Madeleine Armstrong
    
   - 12/08/2023 - 13:10

3. Investors brush off Car-T scare

   … Autolus Ph1 Mcarty ** in ≥4L MM, data due at ASH 2023 Equecabtagene autoleucel IASO … Ph1 Mcarty ^^ (NCT04795882) in ≥4L MM, data due at ASH 2023 KITE-363* Gilead Ph1 ( NCT04989803 ) …

   
    

   Madeleine Armstrong
    
   - 12/04/2023 - 16:23

4. ASH 2023 preview – Darzalex gets a first-line boost from Perseus

   ASH 2023 preview – Darzalex gets a first-line boost from …

   
    

   Madeleine Armstrong
    
   - 11/27/2023 - 14:22

5. ASH 2023 preview – Syndax gets an edge on Kura

   ASH 2023 preview – Syndax gets an edge on Kura …

   
    

   Madeleine Armstrong
    
   - 11/27/2023 - 13:15

6. ASH 2023 preview – small-molecule duels

   ASH 2023 preview – small-molecule duels …

   
    

   Jacob Plieth
    
   - 11/07/2023 - 13:55

7. ASH 2023 preview – the first cell therapy winners

   ASH 2023 preview – the first cell therapy winners …

   
    

   Jacob Plieth
    
   - 09/06/2024 - 10:03

8. Jacob Plieth

   Jacob Plieth …